Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells.

The enumeration of antigen-specific T cell responses has been greatly facilitated in recent years by the development of methods based on the detection of cytokines. In particular, the enzyme-linked immunospot (ELISPOT) and cytokine flow cytometry (CFC) assays have become popular. Since both assays are likely to continue to be in widespread use, it is important to evaluate whether their results are comparable. In the current study, we compared the results obtained in the ELISPOT and CFC assays using peptide pools corresponding to CMV and HIV-1 proteins in chronically HIV-1-infected individuals. Analysis of T cell responses to peptide pools indicated that the CMV pp65 and HIV-1 Gag CFC and ELISPOT-derived results were statistically correlated. However, the results obtained with each assay differed in important ways: the magnitude of the response was consistently higher in the CFC assay while the CFC assay was less likely than the ELISPOT assay to detect low-level responses. Furthermore, there was a lack of numeric agreement between ELISPOT and CFC results. For studies that require the detection of low-level responses, or definition of responses as positive or negative, the ELISPOT assay may be preferable. In contrast, the CFC has a greater dynamic range and allows for phenotypic discrimination of responding cells, making it the assay of choice for most other applications.

[1]  J. Schneider-Mergener,et al.  T-cell epitope mapping by flow cytometry , 1998, Nature Medicine.

[2]  A. P. Warren,et al.  Ex vivo detection and enumeration of human antigen-specific CD8+ T lymphocytes using antigen delivery by a recombinant vaccinia expression vector and intracellular cytokine staining. , 2002, Journal of immunological methods.

[3]  A. Trkola,et al.  HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. , 1999, The Journal of clinical investigation.

[4]  D. Nixon,et al.  Functional Heterogeneity of Cytokines and Cytolytic Effector Molecules in Human CD8+ T Lymphocytes1 , 2001, The Journal of Immunology.

[5]  A. McMichael,et al.  Rapid Effector Function in CD8+ Memory T Cells , 1997, The Journal of experimental medicine.

[6]  R. Koup,et al.  Analysis of Total Human Immunodeficiency Virus (HIV)-Specific CD4+ and CD8+ T-Cell Responses: Relationship to Viral Load in Untreated HIV Infection , 2001, Journal of Virology.

[7]  D. Sackett,et al.  The Ends of Human Life: Medical Ethics in a Liberal Polity , 1992, Annals of Internal Medicine.

[8]  C. Pitcher,et al.  Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. , 2001, Journal of immunological methods.

[9]  R. Steinman,et al.  A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. , 1999, AIDS.

[10]  J. Lieberman,et al.  The functional CD8 T cell response to HIV becomes type-specific in progressive disease. , 2002, The Journal of clinical investigation.

[11]  S. Rowland-Jones,et al.  Cellular immune responses to HIV , 2001, Nature.

[12]  G. M. Ortiz,et al.  Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. , 2000, The Journal of infectious diseases.

[13]  R. Koup,et al.  Monitoring HIV-specific CD8+ T cell responses by intracellular cytokine production. , 2001, Immunology letters.

[14]  B. Chapuis,et al.  Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. , 1968, Immunology.

[15]  V. Maino,et al.  Direct functional analysis of epitope-specific CD8+ T cells in peripheral blood. , 2001, Viral immunology.

[16]  F. Plata.  HIV-specific cytotoxic T lymphocytes. , 1989, Research in immunology.

[17]  Sylvia Janetzki,et al.  A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. , 2002, Journal of immunological methods.

[18]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[19]  M. Clerici,et al.  Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. , 1989, The Journal of clinical investigation.

[20]  O Ouchterlony,et al.  Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. , 1988, Journal of immunological methods.

[21]  H. Volk,et al.  Analysis of CD8 T cell reactivity to cytomegalovirus using protein‐spanning pools of overlapping pentadecapeptides , 2000, European journal of immunology.

[22]  D. Nixon,et al.  HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides , 1988, Nature.

[23]  R. Koup,et al.  Putative Immunodominant Human Immunodeficiency Virus-Specific CD8+ T-Cell Responses Cannot Be Predicted by Major Histocompatibility Complex Class I Haplotype , 2000, Journal of Virology.

[24]  E. Rosenberg,et al.  Rapid Definition of Five Novel HLA-A∗3002-Restricted Human Immunodeficiency Virus-Specific Cytotoxic T-Lymphocyte Epitopes by Elispot and Intracellular Cytokine Staining Assays , 2001, Journal of Virology.

[25]  D. Nixon,et al.  Rapid quantification of SIV-specific CD8 T cell responses with recombinant vaccinia virus ELISPOT or cytokine flow cytometry. , 2000, AIDS.

[26]  G. Carcelain,et al.  A systematic comparison of methods to measure HIV-1 specific CD8 T cells. , 2003, Journal of immunological methods.

[27]  V. Maino,et al.  Immunofluorescence Analysis of T-Cell Responses in Health and Disease , 2000, Journal of Clinical Immunology.

[28]  Jeffrey N. Martin,et al.  T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. , 2003, The Journal of infectious diseases.

[29]  B. Walker,et al.  Immunologic control of HIV-1. , 2002, Annual review of medicine.

[30]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.

[31]  J. Yewdell,et al.  Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function. , 1990, Current topics in microbiology and immunology.

[32]  B. Walker,et al.  HIV-specific cytotoxic T lymphocytes in seropositive individuals , 1987, Nature.

[33]  E. Thiel,et al.  Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells. , 2001, Journal of immunological methods.